Evaluation of the Effectiveness of Implementation of Additional Risk Minimization Measures (aRMM) Materials for Xeljanz® (Tofacitinib) / Rheumatoid Arthritis (RA) indication in Nigeria via a Survey among Prescribers: A Non-Interventional Post Authorization Safety Study (PASS).

Data sources

• Data source(s), other:
  Survey among Prescribers

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  Unknown